Literature DB >> 6352632

Pharmacokinetics and tissue penetration of ceftazidime: studies on lymph, aqueous humour, skin blister, cerebrospinal and pleural fluid.

R A Walstad, K B Hellum, S Blika, L G Dale, T Fredriksen, K I Myhre, G R Spencer.   

Abstract

The elimination kinetics and penetration of ceftazidime into skin blister and lymphatic fluid were studied in nine healthy volunteers following a 1 g iv bolus injection. From the concentration time curve in plasma the following pharmacokinetic parameters (mean +/- S.D.) were calculated: elimination half-life 1.85 +/- 0.33 h; area under the curves 127 +/- 12 mg . h/l; apparent volume of distribution: 21.1 +/- 2.61; total plasma clearance: 133 +/- 13 ml/min and renal clearance: 109 +/- 7 ml/min. Urine recovery after 8 h was 82% of the administered dose. Nearly the same elimination rate constant, half-life and area under the curve were demonstrated for blister fluid and lymph. The penetration of ceftazidime into cerebrospinal fluid (n = 19), aqueous humour (n = 21) and pleural effusions (n = 5) were studied in patients after a 2 g iv bolus injection. In patients with normal meninges (n = 14) the penetration was poor: the concentrations were less than 1 mg/l. In patients with meningitis (n = 5) levels of 18, 17, 16, 1 and 0.8 mg/l were found. Aqueous humour penetration was satisfactory, and a mean concentration of 11 +/- 4 mg/l corresponding to a penetration ratio of 19% was found. The penetration of ceftazidime into large pleural effusions was also good with concentrations from 17 +/- 3 to 28 +/- 2 mg/l, corresponding to a mean penetration ratio of 38%.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6352632     DOI: 10.1093/jac/12.suppl_a.275

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  20 in total

Review 1.  Ocular drug delivery. Pharmacokinetic considerations.

Authors:  R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

2.  Pharmacokinetics and tissue concentrations of ceftazidime in burn patients.

Authors:  R A Walstad; L Aanderud; E Thurmann-Nielsen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Influence of changes in pancreatic tissue morphology and capillary blood flow on antibiotic tissue concentrations in the pancreas during the progression of acute pancreatitis.

Authors:  T Foitzik; H G Hotz; M Kinzig; F Sörgel; H J Buhr
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

4.  Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil.

Authors:  M T Borin; G S Hughes; C R Spillers; R K Patel
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 5.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

6.  Ceftazidime in neonatal infections.

Authors:  D C Low; J G Bissenden; R Wise
Journal:  Arch Dis Child       Date:  1985-04       Impact factor: 3.791

7.  Pharmacokinetics of ceftazidime in patients with biliary tract disease.

Authors:  R A Walstad; J N Wiig; E Thurmann-Nielsen; T B Halvorsen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Severe Keratitis Caused by Pseudomonas aeruginosa Successfully Treated with Ceftazidime Associated with Acetazolamide.

Authors:  Benoit Hue; Marc Doat; Gilles Renard; Marie-Laure Brandely; François Chast
Journal:  J Ophthalmol       Date:  2009-04-26       Impact factor: 1.909

9.  Cerebrospinal fluid ceftazidime kinetics in patients with external ventriculostomies.

Authors:  R Nau; H W Prange; M Kinzig; A Frank; A Dressel; P Scholz; H Kolenda; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

10.  Antimicrobial pharmacokinetics in endophthalmitis treatment: studies of ceftazidime.

Authors:  T A Meredith
Journal:  Trans Am Ophthalmol Soc       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.